Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma

Clinical trial NCT01473095 · COMPLETED

Trial details

NCT number: NCT01473095
Sponsor: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Solid Tumor Malignant Lymphoma Tumor

Start date: 2011-11-01
Primary completion: 2017-07-06
Enrollment: 120

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.